Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H24N2O4 |
Molecular Weight | 344.4049 |
Optical Activity | ( - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(C[C@@H](C)NC[C@H](O)C2=CC=C(O)C(NC=O)=C2)C=C1
InChI
InChIKey=BPZSYCZIITTYBL-YJYMSZOUSA-N
InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1
Molecular Formula | C19H24N2O4 |
Molecular Weight | 344.4049 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/14725487
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/14725487
Sepracor in the US is developing arformoterol [R,R-formoterol], a single isomer form of the beta(2)-adrenoceptor agonist formoterol [eformoterol]. This isomer contains two chiral canters and is being developed as an inhaled preparation for the treatment of respiratory disorders. Sepracor believes that arformoterol has the potential to be a once-daily therapy with a rapid onset of action and a duration of effect exceeding 12 hours. Sepracor stated in July 2003 that it had completed more than 100 preclinical studies and initiated or completed 15 clinical studies for arformoterol inhalation solution for the treatment of bronchospasm in patients with COPD. The pharmacologic effects of beta2-adrenoceptor agonist drugs, including arformoterol, are at least in part attributable to stimulation of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3′,5′-adenosine monophosphate (cyclic AMP). Increased intracellular cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. In vitro tests show that arformoterol is an inhibitor of the release of mast cell mediators, such as histamine and leukotrienes, from the human lung. Arformoterol also inhibits histamine-induced plasma albumin extravasation in anesthetized guinea pigs and inhibits allergen-induced eosinophil influx in dogs with airway hyper-responsiveness. The relevance of these in vitro and animal findings to humans is unknown.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL210 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20406080 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | BROVANA Approved UseBROVANA Inhalation Solution is a long-acting beta2-adrenergic agonist (beta2-agonist) indicated for: Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. (1.1) Important limitations of use: BROVANA Inhalation Solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease. (1.2, 5.2) BROVANA Inhalation Solution is not indicated to treat asthma. (1.2) 1.1 Maintenance Treatment of COPD BROVANA (arformoterol tartrate) Inhalation Solution is indicated for the long-term, twice daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. BROVANA Inhalation Solution is for use by nebulization only. 1.2 Important Limitations of Use BROVANA Inhalation Solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease [see WARNINGS AND PRECAUTIONS (5.2) Launch Date1.16009284E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.3 pg/mL |
15 μg 2 times / day steady-state, respiratory dose: 15 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: |
ARFORMOTEROL plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
26.65 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24746942 |
24 μg single, respiratory dose: 24 μg route of administration: Respiratory experiment type: SINGLE co-administered: BECLOMETHASONE 17-MONOPROPIONATE |
FORMOTEROL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
22.3 nM |
10 μg single, respiratory dose: 10 μg route of administration: Respiratory experiment type: SINGLE co-administered: MOMETASONE FUROATE |
FORMOTEROL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
34.5 pg × h/mL |
15 μg 2 times / day steady-state, respiratory dose: 15 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: |
ARFORMOTEROL plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
104.52 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24746942 |
24 μg single, respiratory dose: 24 μg route of administration: Respiratory experiment type: SINGLE co-administered: BECLOMETHASONE 17-MONOPROPIONATE |
FORMOTEROL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
33.7 pM × h |
10 μg single, respiratory dose: 10 μg route of administration: Respiratory experiment type: SINGLE co-administered: MOMETASONE FUROATE |
FORMOTEROL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
26 h |
15 μg 2 times / day steady-state, respiratory dose: 15 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: |
ARFORMOTEROL plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
4.71 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24746942 |
24 μg single, respiratory dose: 24 μg route of administration: Respiratory experiment type: SINGLE co-administered: BECLOMETHASONE 17-MONOPROPIONATE |
FORMOTEROL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
48% |
15 μg 2 times / day steady-state, respiratory dose: 15 μg route of administration: Respiratory experiment type: STEADY-STATE co-administered: |
ARFORMOTEROL plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
37.5% |
FORMOTEROL plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
20 ug 2 times / day steady, respiratory Recommended Dose: 20 ug, 2 times / day Route: respiratory Route: steady Dose: 20 ug, 2 times / day Sources: |
unhealthy, 40-90 years n = 123 Health Status: unhealthy Condition: COPD Age Group: 40-90 years Sex: M+F Population Size: 123 Sources: |
Other AEs: Diarrhea, Nausea... Other AEs: Diarrhea (6%) Sources: Nausea (6%) Nasopharyngitis (4%) Dry mouth (4%) Vomiting (3%) Dizziness (3%) Insomnia (3%) |
25 ug 2 times / day multiple, respiratory Highest studied dose Dose: 25 ug, 2 times / day Route: respiratory Route: multiple Dose: 25 ug, 2 times / day Sources: Page: p.21 |
unhealthy, 63.8 n = 147 Health Status: unhealthy Condition: Chronic obstructive pulmonary disease Age Group: 63.8 Sex: M+F Population Size: 147 Sources: Page: p.21 |
|
30 ug 2 times / day multiple, respiratory (total) Recommended Dose: 30 ug, 2 times / day Route: respiratory Route: multiple Dose: 30 ug, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Chronic obstructive pulmonary disease Sources: Page: p.1 |
Disc. AE: Bronchospasm paradoxical... AEs leading to discontinuation/dose reduction: Bronchospasm paradoxical (grade 4) Sources: Page: p.1 |
15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Other AEs: Angina pectoris, Angina unstable... Other AEs: Angina pectoris (serious, 3 patients) Sources: Angina unstable (serious, 1 patient) Atrial fibrillation (serious, 3 patients) Cardio-respiratory arrest (serious, 2 patients) Cor pulmonale (serious, 1 patient) Coronary artery disease (serious, 3 patients) Myocardial ischaemia (serious, 1 patient) Vertigo (serious, 1 patient) Iridocyclitis (serious, 1 patient) Barrett's oesophagus (serious, 1 patient) Diverticular perforation (serious, 1 patient) Gastric ulcer haemorrhage (serious, 1 patient) Gastritis erosive (serious, 1 patient) Hiatus hernia (serious, 1 patient) Intestinal perforation (serious, 1 patient) Pancreatitis acute (serious, 1 patient) Non-cardiac chest pain (serious, 3 patients) Oedema peripheral (serious, 1 patient) Cholecystitis (serious, 1 patient) Bronchopneumonia (serious, 1 patient) Clostridial infection (serious, 1 patient) Clostridium difficile colitis (serious, 1 patient) Gastroenteritis bacterial (serious, 1 patient) Osteomyelitis (serious, 1 patient) Osteotomy (serious, 1 patient) Osteomyelitis acute (serious, 1 patient) Postoperative wound infection (serious, 1 patient) Sepsis (serious, 3 patients) Urinary tract infection (serious, 1 patient) Accidental overdose (serious, 1 patient) Ankle fracture (serious, 1 patient) Cervical vertebral fracture (serious, 1 patient) Head injury (serious, 1 patient) Incisional hernia (serious, 1 patient) Open wound (serious, 1 patient) Tibia fracture (serious, 1 patient) Muscular weakness (serious, 1 patient) Rotator cuff syndrome (serious, 1 patient) Brain neoplasm (serious, 1 patient) Metastases to lymph nodes (serious, 1 patient) Oesophageal carcinoma (serious, 1 patient) Squamous cell carcinoma (serious, 1 patient) Throat cancer (serious, 1 patient) Carotid artery disease (serious, 1 patient) Headache (serious, 1 patient) Ischaemic stroke (serious, 1 patient) Sensory disturbance (serious, 1 patient) Transient ischaemic attack (serious, 1 patient) Major depression (serious, 2 patients) Mental status changes (serious, 1 patient) Nephropathy (serious, 1 patient) Renal artery stenosis (serious, 1 patient) Renal failure (serious, 1 patient) Acute respiratory distress syndrome (serious, 1 patient) Bronchiectasis (serious, 1 patient) Hypoxia (serious, 1 patient) Respiratory arrest (serious, 1 patient) Urticaria (serious, 1 patient) Aortic aneurysm (serious, 1 patient) Hypertensive crisis (serious, 1 patient) Hypotension (serious, 1 patient) Iliac artery stenosis (serious, 2 patients) Peripheral arterial occlusive disease (serious, 1 patient) Bronchitis (below serious, 43 patients) Nasopharyngitis (below serious, 38 patients) Upper respiratory tract infection (below serious, 22 patients) Headache (below serious, 35 patients) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Dizziness | 3% | 20 ug 2 times / day steady, respiratory Recommended Dose: 20 ug, 2 times / day Route: respiratory Route: steady Dose: 20 ug, 2 times / day Sources: |
unhealthy, 40-90 years n = 123 Health Status: unhealthy Condition: COPD Age Group: 40-90 years Sex: M+F Population Size: 123 Sources: |
Insomnia | 3% | 20 ug 2 times / day steady, respiratory Recommended Dose: 20 ug, 2 times / day Route: respiratory Route: steady Dose: 20 ug, 2 times / day Sources: |
unhealthy, 40-90 years n = 123 Health Status: unhealthy Condition: COPD Age Group: 40-90 years Sex: M+F Population Size: 123 Sources: |
Vomiting | 3% | 20 ug 2 times / day steady, respiratory Recommended Dose: 20 ug, 2 times / day Route: respiratory Route: steady Dose: 20 ug, 2 times / day Sources: |
unhealthy, 40-90 years n = 123 Health Status: unhealthy Condition: COPD Age Group: 40-90 years Sex: M+F Population Size: 123 Sources: |
Dry mouth | 4% | 20 ug 2 times / day steady, respiratory Recommended Dose: 20 ug, 2 times / day Route: respiratory Route: steady Dose: 20 ug, 2 times / day Sources: |
unhealthy, 40-90 years n = 123 Health Status: unhealthy Condition: COPD Age Group: 40-90 years Sex: M+F Population Size: 123 Sources: |
Nasopharyngitis | 4% | 20 ug 2 times / day steady, respiratory Recommended Dose: 20 ug, 2 times / day Route: respiratory Route: steady Dose: 20 ug, 2 times / day Sources: |
unhealthy, 40-90 years n = 123 Health Status: unhealthy Condition: COPD Age Group: 40-90 years Sex: M+F Population Size: 123 Sources: |
Diarrhea | 6% | 20 ug 2 times / day steady, respiratory Recommended Dose: 20 ug, 2 times / day Route: respiratory Route: steady Dose: 20 ug, 2 times / day Sources: |
unhealthy, 40-90 years n = 123 Health Status: unhealthy Condition: COPD Age Group: 40-90 years Sex: M+F Population Size: 123 Sources: |
Nausea | 6% | 20 ug 2 times / day steady, respiratory Recommended Dose: 20 ug, 2 times / day Route: respiratory Route: steady Dose: 20 ug, 2 times / day Sources: |
unhealthy, 40-90 years n = 123 Health Status: unhealthy Condition: COPD Age Group: 40-90 years Sex: M+F Population Size: 123 Sources: |
Bronchospasm paradoxical | grade 4 Disc. AE |
30 ug 2 times / day multiple, respiratory (total) Recommended Dose: 30 ug, 2 times / day Route: respiratory Route: multiple Dose: 30 ug, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Chronic obstructive pulmonary disease Sources: Page: p.1 |
Upper respiratory tract infection | below serious, 22 patients | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Headache | below serious, 35 patients | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Nasopharyngitis | below serious, 38 patients | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Bronchitis | below serious, 43 patients | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Accidental overdose | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Acute respiratory distress syndrome | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Angina unstable | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Ankle fracture | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Aortic aneurysm | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Barrett's oesophagus | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Brain neoplasm | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Bronchiectasis | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Bronchopneumonia | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Carotid artery disease | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Cervical vertebral fracture | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Cholecystitis | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Clostridial infection | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Clostridium difficile colitis | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Cor pulmonale | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Diverticular perforation | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Gastric ulcer haemorrhage | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Gastritis erosive | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Gastroenteritis bacterial | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Head injury | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Headache | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Hiatus hernia | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Hypertensive crisis | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Hypotension | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Hypoxia | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Incisional hernia | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Intestinal perforation | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Iridocyclitis | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Ischaemic stroke | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Mental status changes | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Metastases to lymph nodes | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Muscular weakness | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Myocardial ischaemia | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Nephropathy | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Oedema peripheral | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Oesophageal carcinoma | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Open wound | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Osteomyelitis acute | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Osteomyelitis | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Osteotomy | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Pancreatitis acute | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Peripheral arterial occlusive disease | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Postoperative wound infection | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Renal artery stenosis | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Renal failure | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Respiratory arrest | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Rotator cuff syndrome | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Sensory disturbance | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Squamous cell carcinoma | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Throat cancer | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Tibia fracture | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Transient ischaemic attack | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Urinary tract infection | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Urticaria | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Vertigo | serious, 1 patient | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Cardio-respiratory arrest | serious, 2 patients | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Iliac artery stenosis | serious, 2 patients | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Major depression | serious, 2 patients | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Angina pectoris | serious, 3 patients | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Atrial fibrillation | serious, 3 patients | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Coronary artery disease | serious, 3 patients | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Non-cardiac chest pain | serious, 3 patients | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Sepsis | serious, 3 patients | 15 ug 2 times / day steady, respiratory Dose: 15 ug, 2 times / day Route: respiratory Route: steady Dose: 15 ug, 2 times / day Sources: |
unhealthy n = 420 Health Status: unhealthy Condition: COPD Population Size: 420 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 38.0 |
inconclusive | |||
Page: (ClinPharm1) 11, 14, (ClinPharm2) 4-7 |
moderate [Ki 33 uM] | |||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
Page: 28.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20831_Foradil_clinphrmr_P2.pdf#page=4 Page: (ClinPharm2) 4-7 |
no | |||
Page: 37, 52 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20831_Foradil_clinphrmr_P2.pdf#page=4 Page: (ClinPharm2) 4-7 |
no | |||
Page: 37, 52 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20831_Foradil_clinphrmr_P2.pdf#page=4 Page: (ClinPharm2) 4-7 |
no | |||
Page: 37, 52 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20831_Foradil_clinphrmr_P2.pdf#page=4 Page: (ClinPharm2) 4-7 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20831_Foradil_clinphrmr_P2.pdf#page=4 Page: (ClinPharm2) 4-7 |
no | |||
Page: 37.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20831_Foradil_clinphrmr_P2.pdf#page=4 Page: (ClinPharm2) 4-7 |
no | |||
Page: 37.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20831_Foradil_clinphrmr_P2.pdf#page=4 Page: (ClinPharm2) 4-7 |
no | |||
Page: 37.0 |
no | |||
Page: 37, 52 |
no | no (co-administration study) Comment: coadministration with paroxetine did not affect exposure to either drug Page: 37, 52 |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 38.0 |
inconclusive | |||
Page: (Label1) 4, (Label2) 14, (ClinPharm1) 11, 14, (ClinPharm2) 2-3 |
major | |||
Page: (Label1) 4, (ClinPharm1) 11, 14, (ClinPharm2) 2-3 |
minor | |||
Page: (Label1) 4, (Label2) 14, (ClinPharm1) 11, 14, (ClinPharm2) 2-3 |
minor | |||
Page: (Label1) 4, (Label2) 14, (ClinPharm1) 11, 14, (ClinPharm2) 2-3 |
minor | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20831_Foradil_clinphrmr_P2.pdf#page=2 Page: (ClinPharm2) 2-3, , (PMDA) 16 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20831_Foradil_clinphrmr_P2.pdf#page=2 Page: (ClinPharm2) 2-3, (PMDA) 16 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/20831_Foradil_clinphrmr_P2.pdf#page=2 Page: (ClinPharm2) 2-3, (PMDA) 16 |
no | |||
weak | ||||
Page: 17.0 |
yes | |||
yes | ||||
Page: 28.0 |
yes | |||
Page: 28.0 |
yes | |||
yes | ||||
yes | ||||
Page: 28.0 |
yes | |||
yes | ||||
Page: 28.0 |
yes | |||
yes | ||||
Page: 28.0 |
yes | |||
Page: 17, 37 |
yes | no (co-administration study) Comment: coadministration with paroxetine caused a slight increase in paroxetine; dose adjustment is not required when coadministered with therapeutic agents that are potent inhibitors of CYP2D6 Page: 17, 37 |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 25, 29 |
PubMed
Title | Date | PubMed |
---|---|---|
Long-acting beta-agonist treatment in patients with persistent asthma already receiving inhaled corticosteroids. | 2001 |
|
Nocturnal asthma uncontrolled by inhaled corticosteroids: theophylline or long-acting beta2 agonists? | 2001 |
|
Inhaled budesonide/formoterol combination. | 2001 |
|
Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD. | 2001 |
|
Similar efficacy following four weeks treatment of asthmatics with formoterol 12 micrograms b.d. delivered by two different dry powder inhalers: differences in inhaler handling. | 2001 Apr |
|
Formoterol used as needed--clinical effectiveness. | 2001 Aug |
|
Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. | 2001 Aug |
|
Safety of formoterol Turbuhaler at cumulative dose of 90 microg in patients with acute bronchial obstruction. | 2001 Dec |
|
Development of a lyophilized formulation for (R,R)-formoterol (L)-tartrate. | 2001 Jan |
|
Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists. | 2001 Jul |
|
Adding formoterol to budesonide in moderate asthma--health economic results from the FACET study. | 2001 Jun |
|
Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol. | 2001 Mar |
|
Single-isomer beta-agonists. | 2001 Mar |
|
In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium : a 3-week, randomized, double-blind, within-patient, multicenter study. | 2001 May |
|
A placebo-controlled clinical trial of regular monotherapy with short-acting and long-acting beta(2)-agonists in allergic asthmatic patients. | 2001 May |
|
[Precise direction or flexible self-control. How strictly must the asthma patient adhere to medical advice?]. | 2001 May 10 |
|
Formoterol (Foradil Aerolizer) for asthma. | 2001 May 14 |
|
Glaucoma associated with metered-dose bronchodilator therapy. | 2001 Oct |
|
Statistical issues in bioequivalence [correction of bioequivalance]. | 2001 Sep 15-30 |
|
Formoterol Turbuhaler 4.5 microg (delivered dose) has a rapid onset and 12-h duration of bronchodilation. | 2002 |
|
Biological actions of formoterol isomers. | 2002 |
|
Onset of action following formoterol Turbuhaler and salbutamol pMDI in reversible chronic airway obstruction. | 2002 |
|
Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease. | 2002 Apr |
|
Cost-effectiveness of eformoterol Turbohaler versus salmeterol Accuhaler in children with symptomatic asthma. | 2002 Apr |
|
Dose-related effects of formoterol on airway responsiveness to adenosine 5'-monophosphate and histamine. | 2002 Apr |
|
A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and beta-agonist treatment on IL-10 serum levels in children with asthma. | 2002 Feb |
|
The role of inflammation and anti-inflammatory medication in asthma. | 2002 Feb |
|
Symbicort: controlling asthma in adults. | 2002 Feb |
|
The safety and efficacy of formoterol (Oxis) turbuhaler plus budesonide (Pulmicort) turbuhaler in mild to moderate asthma: a comparison with budesonide Turbuhaler alone and current non-corticosteroid therapy in Russia. | 2002 Jan-Feb |
|
Low-dose budesonide improved asthma control in mild asthma; adding formoterol improved control in corticosteroid-treated patients. | 2002 Jul-Aug |
|
Beta-adrenoceptor agonists and asthma--100 years of development. | 2002 Jun 7 |
|
[Effect of triamcinolone acetonide, montelukast, nedocromil sodium and formoterol on eosinophil blood counts, ECP serum levels and clinical progression of asthma in children]. | 2002 Mar |
|
Additive anti-inflammatory effect of formoterol and budesonide on human lung fibroblasts. | 2002 Mar |
|
New therapeutic drugs in the management of chronic obstructive pulmonary disease. | 2002 Mar |
|
Quantification of terbutaline in urine by enzyme-linked immunosorbent assay and capillary electrophoresis after oral and inhaled administrations. | 2002 Mar 5 |
|
Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma. | 2002 May |
|
Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. | 2002 May |
|
Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline. | 2002 May |
|
Comparison of the effects of salmeterol and formoterol in patients with severe asthma. | 2002 May |
Patents
Sample Use Guides
15 ug administered twice a day (morning and evening) by nebulization. A total daily dose greater than 30 ug (15 ug twice daily) is not recommended. BROVANA (arformoterol tartrate) should be administered by the inhaled route via a standard jet nebulizer connected to an air compressor
Route of Administration:
Respiratory
In Vitro Use Guide
Curator's Comment: In vitro tests show that arformoterol is an inhibitor of the release of mast cell mediators, such as histamine and leukotrienes, from the human lung. Arformoterol also inhibits histamine-induced plasma albumin extravasation in anesthetized guinea pigs and inhibits allergen-induced eosinophil influx in dogs with airway hyper-responsiveness.
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Thu Jul 06 22:53:45 UTC 2023
by
admin
on
Thu Jul 06 22:53:45 UTC 2023
|
Record UNII |
F91H02EBWT
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000009922
Created by
admin on Thu Jul 06 22:53:45 UTC 2023 , Edited by admin on Thu Jul 06 22:53:45 UTC 2023
|
||
|
NDF-RT |
N0000175779
Created by
admin on Thu Jul 06 22:53:45 UTC 2023 , Edited by admin on Thu Jul 06 22:53:45 UTC 2023
|
||
|
NCI_THESAURUS |
C48149
Created by
admin on Thu Jul 06 22:53:45 UTC 2023 , Edited by admin on Thu Jul 06 22:53:45 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000128220
Created by
admin on Thu Jul 06 22:53:45 UTC 2023 , Edited by admin on Thu Jul 06 22:53:45 UTC 2023
|
PRIMARY | |||
|
ARFORMOTEROL
Created by
admin on Thu Jul 06 22:53:45 UTC 2023 , Edited by admin on Thu Jul 06 22:53:45 UTC 2023
|
PRIMARY | |||
|
M5542
Created by
admin on Thu Jul 06 22:53:45 UTC 2023 , Edited by admin on Thu Jul 06 22:53:45 UTC 2023
|
PRIMARY | Merck Index | ||
|
C61641
Created by
admin on Thu Jul 06 22:53:45 UTC 2023 , Edited by admin on Thu Jul 06 22:53:45 UTC 2023
|
PRIMARY | |||
|
304962
Created by
admin on Thu Jul 06 22:53:45 UTC 2023 , Edited by admin on Thu Jul 06 22:53:45 UTC 2023
|
PRIMARY | RxNorm | ||
|
F91H02EBWT
Created by
admin on Thu Jul 06 22:53:45 UTC 2023 , Edited by admin on Thu Jul 06 22:53:45 UTC 2023
|
PRIMARY | |||
|
3083544
Created by
admin on Thu Jul 06 22:53:45 UTC 2023 , Edited by admin on Thu Jul 06 22:53:45 UTC 2023
|
PRIMARY | |||
|
F91H02EBWT
Created by
admin on Thu Jul 06 22:53:45 UTC 2023 , Edited by admin on Thu Jul 06 22:53:45 UTC 2023
|
PRIMARY | |||
|
Arfomoterol
Created by
admin on Thu Jul 06 22:53:45 UTC 2023 , Edited by admin on Thu Jul 06 22:53:45 UTC 2023
|
PRIMARY | |||
|
8398
Created by
admin on Thu Jul 06 22:53:45 UTC 2023 , Edited by admin on Thu Jul 06 22:53:45 UTC 2023
|
PRIMARY | |||
|
408174
Created by
admin on Thu Jul 06 22:53:45 UTC 2023 , Edited by admin on Thu Jul 06 22:53:45 UTC 2023
|
PRIMARY | |||
|
SUB35021
Created by
admin on Thu Jul 06 22:53:45 UTC 2023 , Edited by admin on Thu Jul 06 22:53:45 UTC 2023
|
PRIMARY | |||
|
DTXSID40110071
Created by
admin on Thu Jul 06 22:53:45 UTC 2023 , Edited by admin on Thu Jul 06 22:53:45 UTC 2023
|
PRIMARY | |||
|
C012629
Created by
admin on Thu Jul 06 22:53:45 UTC 2023 , Edited by admin on Thu Jul 06 22:53:45 UTC 2023
|
PRIMARY | |||
|
DB01274
Created by
admin on Thu Jul 06 22:53:45 UTC 2023 , Edited by admin on Thu Jul 06 22:53:45 UTC 2023
|
PRIMARY | |||
|
7479
Created by
admin on Thu Jul 06 22:53:45 UTC 2023 , Edited by admin on Thu Jul 06 22:53:45 UTC 2023
|
PRIMARY | |||
|
67346-49-0
Created by
admin on Thu Jul 06 22:53:45 UTC 2023 , Edited by admin on Thu Jul 06 22:53:45 UTC 2023
|
PRIMARY | |||
|
4943
Created by
admin on Thu Jul 06 22:53:45 UTC 2023 , Edited by admin on Thu Jul 06 22:53:45 UTC 2023
|
PRIMARY | |||
|
CHEMBL1363
Created by
admin on Thu Jul 06 22:53:45 UTC 2023 , Edited by admin on Thu Jul 06 22:53:45 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> AGONIST |
SHORT-ACTING
|
||
|
BINDER->LIGAND |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||